花园生物2月25日获融资买入3778.56万元，融资余额7.87亿元

Core Viewpoint - Garden Biologics has shown fluctuations in financing activities and stock performance, with a notable decrease in net profit and revenue in recent financial reports [1][2]. Financing Activities - On February 25, Garden Biologics experienced a financing buy-in of 37.78 million yuan, while the financing repayment amounted to 57.76 million yuan, resulting in a net financing outflow of 19.98 million yuan [1]. - The total financing and margin trading balance for Garden Biologics reached 789 million yuan, with the financing balance accounting for 8.47% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, 500 shares were repaid, and 800 shares were sold on February 25, with a selling amount of 13,700 yuan, while the securities lending balance was 2.31 million yuan, also at a high level compared to the past year [1]. Company Overview - Zhejiang Garden Biologics Co., Ltd. was established on December 18, 2000, and went public on October 9, 2014. The company focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1]. - The main revenue sources for the company include vitamin products (47.41%), pharmaceuticals (30.22%), lanolin and its derivatives (20.93%), and other minor categories [1]. Shareholder Information - As of February 10, the number of shareholders for Garden Biologics increased by 2.92% to 24,300, while the average circulating shares per person decreased by 2.84% to 22,025 shares [2]. - Cumulatively, the company has distributed 446 million yuan in dividends since its A-share listing, with 178 million yuan distributed over the past three years [3]. - Among the top ten circulating shareholders, the Southern CSI 1000 ETF holds 3.48 million shares, a decrease of 48,400 shares from the previous period [3].